| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6073902 | Journal of the American Academy of Dermatology | 2013 | 8 Pages |
Abstract
There is a significant risk of developing rash in patients with cancer receiving ipilimumab. There was no statistically significant difference in the risk of rash based on dose or underlying tumor. Adequate monitoring and early intervention are recommended to prevent decreased quality of life and inconsistent dosing.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Kira MD, PhD, Benjamin C. BA, Shenhong MD, PhD, Melissa P. MD, Mario E. MD,